CEO Keith Valentine says: "Our priorities for 2021 are very similar to those, which I believe we have executed on very well in the past. Namely, to timely and effectively develop and launch clinically relevant products, to increase the number of core distributors and their exclusivity to SeaSpine, to generate above-market revenue growth through more efficient utilization of our spinal implant sets, and to further expand our gross margins. To that end, we plan to launch more than a dozen products in 2021, the most impactful being the alpha launches of the line extension of Mariner with an adult deformity indication and four additional 3D printed interbody systems and the migration of the many alpha launches we delivered in 2020 to full commercial launch. We expect to exit 2021, generating more than 75% of our U.S. Spinal Implant revenue from new and recently launched systems and more than 65% our U.S. revenue from existing and new core distributors. And we expect to generate between 150 to 250 basis points of gross margin expansion from more efficient utilization of our spinal implant sets and inventory and by gaining additional operating efficiencies from our Irvine manufacturing facility." Comments taken from Q4 earnings conference call transcript.

In a regulatory filing, EchoStar disclosed that its Chief Strategy Officer Anders Johnson bought 20K shares of common stock on February 25th in a total transaction size of $469K, boosting his stake by 653%.

The company "expects 2021 gross profit margins to be between 40% and 44%, taking into account businesses divested in 2020 and early 2021, as well as the impact of the company's cost savings initiatives."

TransMedics Group announced that the FDA's Office of Health Technology 2 has communicated its intent to hold a Circulatory Systems Device Advisory Panel meeting on April 6, 2021 to review TransMedics' premarket approval application for the OCS Heart System. "We are looking forward to this important milestone and to hopefully achieving a positive conclusion of the FDA's review process of our OCS Heart PMA application," said Waleed Hassanein, M.D., CEO.

In an interview on CNBC's Mad Money, Mark McClain said transformation from legacy systems is driving business to the company. "We're trying to give customers a multi-layer level of security," McClain said.

Ready Capital announced that its board of directors declared a prorated dividend of 30c per share of common stock and operating partnership unit. The Prorated Dividend is payable on March 18 to common stockholders and operating partnership unitholders of record as of the close of business on March 15. The Prorated Dividend was declared by the board of directors in accordance with the Agreement and Plan of Merger, dated as of December 6, 2020, by and among Ready Capital, RC Merger Subsidiary, LLC and Anworth Mortgage Asset Corporation relating to the previously announced merger of Ready Capital and Anworth.

The dividend is payable on April 21, 2021 to shareholders of record as of April 5, 2021.